Designing trial endpoints and biomarkers for ER‑100 versus D+Q and rapamycin: matching measures to mechanism

Why different geroscience tools demand different trials

The partial epigenetic reprogramming approach represented by ER‑100 (AAV2‑delivered OSK) and two classes of pharmacologic geroprotectors — senolytics (dasatinib + quercetin, “D+Q”) and mTOR inhibition (rapamycin) — all aim to alter drivers of aging. But they act through distinct mechanisms, reach tissues differently, and therefore require tailored endpoints and biomarker strategies in early human testing. This brief reviews recent developments and outlines practical endpoint choices that reflect mechanistic differences and current translational constraints as of 2026‑05‑09.

Recent status snapshot

• ER‑100: Life Biosciences announced FDA IND clearance for ER‑100 in optic neuropathies and initiated a Phase 1 single‑dose intravitreal study in early 2026; the trial is focused on ocular safety, tolerability and exploratory visual/biomarker signals rather than systemic rejuvenation claims ^[1][2].
• D+Q: Senolytic programs continue to run small, indication‑focused human trials. Pilot data show proof‑of‑concept biomarker and functional signals in limited cohorts (e.g., α‑Klotho and functional gains in small studies), but CSF penetrance and biomarker responses in CNS indications have been mixed ^[6][7][9].
• Rapamycin: Randomized, placebo‑controlled trials of intermittent low‑dose rapamycin in older adults are now producing tolerability and biomarker readouts; safety signals are manageable but functional/healthspan effects remain heterogeneous across trials ^[8].

Match endpoints to mechanism: three short principles

1. Measure the cell‑intrinsic target for interventions that reset state. Partial reprogramming targets epigenetic information and transcriptional programs in treated cells; readouts should include DNA methylation/epigenetic clock measures and cell‑level transcriptomic signatures where feasible.
2. Measure target engagement of pharmacologic clearance or pathway modulation. Senolytics require evidence of senescent cell burden reduction (SASP cytokines, p16/Ink4a expression, tissue biopsies where ethical), plus pharmacokinetics in relevant compartments (e.g., CSF for CNS trials). Rapamycin trials should prioritize pathway biomarkers (mTOR signaling, autophagy markers, immune and metabolic readouts) and functional assays aligned with suspected benefits.
3. Prioritize anatomically and clinically relevant functional endpoints in early phase work. For ER‑100’s ocular program, visual acuity and retinal/optic nerve structural imaging are appropriate primary early readouts; systemic geroscience claims require separate, targeted systemic studies.

Concrete endpoint suggestions, modality by modality

• ER‑100 / OSK (local, gene‑delivery, partial reprogramming)
  • Primary: rigorous ocular safety and tolerability; structural retinal imaging (OCT), electrophysiology and standardized visual function scales tied to the treated tissue.
  • Exploratory molecular: tissue‑restricted epigenetic age signatures (DNA methylation clocks applied to accessible ocular cells where possible) and cell‑type transcriptomic markers that were altered in preclinical AAV‑OSK studies ^[3][4].
  • Translational constraints: AAV biodistribution and immunogenicity limit systemic sampling; the 2026 Phase 1 is designed narrowly to reflect that regulatory caution ^[1][2][5].
• Senolytics (D+Q; intermittent oral dosing)
  • Primary: evidence of senescent cell reduction and SASP downregulation. Combine circulating SASP panels, tissue biomarkers where safe (e.g., adipose or skin biopsy), and functional outcomes relevant to the indication.
  • Pharmacokinetics: measure drug levels in the relevant compartments — notably CSF in CNS trials, since some D+Q components showed limited CSF detectability in a small AD pilot and biomarker responses were mixed ^[6].
  • Exploratory: validated translational markers such as urinary α‑Klotho have been reported to respond in small clinical cohorts and can be included as hypothesis‑generating readouts ^[7].
• Rapamycin (mTOR inhibition)
  • Primary: immune and metabolic biomarkers (e.g., vaccine response modulation, T cell phenotypes, lipid/metabolic panels) and safety/tolerability over intermittent regimens.
  • Functional: domain‑specific measures (muscle function, endothelial health, infection outcomes) rather than a single global “aging” endpoint; recent randomized trials emphasize this targeted approach ^[8].
  • Exploratory: measures of autophagy, phospho‑S6 kinase and other direct mTOR readouts to confirm pathway engagement.

Design implications and realistic expectations

Early human work for all three approaches remains proof‑of‑concept and safety‑focused. ER‑100’s first human study is intentionally narrow (intravitreal, single‑dose, ocular endpoints) and therefore will not provide systemic rejuvenation evidence — it will, however, allow testing of tissue‑level epigenetic/transcriptomic signals in a contained setting ^[1][2][3][5]. Senolytic and rapamycin programs are advancing through multiple small trials that can accumulate evidence across indications, but heterogeneity in biomarkers and PK (e.g., CSF penetration for D+Q) means that cross‑trial comparisons require harmonized panels and pre‑specified translational endpoints ^[6][7][8][9].

Bottom line

As ER‑100 enters ocular first‑in‑human testing and pharmacologic geroprotectors continue iterative clinical development, the most informative early studies will pair mechanism‑aligned biomarkers with clinically meaningful, tissue‑relevant functional endpoints. That strategy both respects regulatory limits on risky systemic claims and builds the comparative evidence base needed to judge whether epigenetic resetting, senescent cell clearance, or pathway modulation delivers distinct or overlapping advantages in human aging biology.

Key sources: See citations below for the trial notices, primary preclinical studies, and recent human trial reports that underpin these recommendations.